Celgene's Tremendous Year Just Got "Tremendouser"
2013 has been a tremendous year for Celgene. But the big biotech's year just got even better.
30 Captivating Facts Celebrating an Important Biotech Breakthrough
The invention of polymerase chain reaction, or PCR, in 1983 may not be directly relevant to everyday investors, but it has gone a long way in spurring innovation in biopharmaceuticals, biotech crops, and industrial biotech. If you own a company in one of those industries, then it's likely that you should pay your respects to PCR.
3 Lessons Big Pharma Learned From BioMarin in 2013
As investors look back at 2013, some of the most compelling lessons for succeeding in treating rare disease have been taught by BioMarin.
Is the Celldex Offering a Reason to Be Scared?
Celldex's offering puts acquisition/partnership rumors by the likes of Roche, Amgen, or Alexion on the back burner. It also raises significant questions prior to a major data release. Does it change the outlook for the Celldex's stock?
High-Risk Pipeline Candidates and Limited Options Make Novartis an Iffy Buy Candidate
With a lot of attention on high-risk programs and unlikely strategic moves, Novartis may struggle to outperform from these levels.